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Background: Myocardial fibrosis is a pathological process that is characterized by disrupted regulation of
extracellular matrix proteins resulting in permanent scarring of the heart tissue and eventual diastolic heart failure.
Pro-fibrotic molecules including transforming growth factor-β and connective tissue growth factor are expressed
early in the AngiotensinII (AngII)-induced and other models of myocardial fibrosis. As such, antibody-based
therapies against these and other targets are currently under development.
Results: In the present study, C57Bl/6 mice were subcutaneously implanted with a mini-osmotic pump containing
either AngII (2.0 μg/kg/min) or saline control for 3 days in combination with mIgG (1 mg/kg/d) injected through
the tail vein. Fibrosis was assessed after picosirius red staining of myocardial cross-sections and was significantly
increased after AngII exposure compared to saline control (11.37 ± 1.41%, 4.94 ± 1.15%; P <0.05). Non-specific mIgG
treatment (1 mg/kg/d) significantly increased the amount of fibrosis (26.34 ± 3.03%; P <0.01). However, when AngII
exposed animals were treated with a Fab fragment of the mIgG or mIgM, this exacerbation of fibrosis was no
longer observed (14.49 ± 2.23%; not significantly different from AngII alone).
Conclusions: These data suggest that myocardial fibrosis was increased by the addition of exogenous non-specific
antibodies in an Fc-mediated manner. These findings could have substantial impact on the future experimental
design of antibody-based therapeutics.
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Despite advances in medical therapy, cardiovascular dis-
ease remains the cause of 33% of all deaths in the United
States and 28% in Canada [1]. Furthermore, the 5-year
mortality rate for patients presenting with heart failure
is 50% [2]. The pathological characteristics and the final
pathway leading to heart failure is the development of
myocardial fibrosis [3]. Myocardial fibrosis is defined as
excess deposition of extracellular matrix (ECM) proteins
within the myocardium and is a significant contributor
to myocardial dysfunction.
A common animal model of myocardial fibrosis is
induction by exposure to AngiotensinII (AngII), a
vasoregulatory hormone, which results in hypertension-* Correspondence: jean.legare@cdha.nshealth.ca
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unless otherwise stated.mediated myocardial fibrosis [4,5]. We, and others, have
previously reported that myocardial fibrosis after expos-
ure to AngII is characterized as early as 3 days by myo-
cardial infiltration of mononuclear cells that have been
defined as bone marrow-derived, monocyte lineage,
fibroblast progenitor cells (fibrocytes) [6-8]. This is
followed by a significant increase in extracellular matrix
deposition, the hallmark of fibrosis.
Using this model, investigators have identified the pro-
fibrotic mediator transforming growth factor-β (TGFβ)
as being central to the regulation of fibrosis develop-
ment. In the AngII-induced model, the TGFβ pathway,
including SMAD phosphorylation and CTGF produc-
tion, are significantly upregulated within the first 3 days,
suggesting their involvement in the initial phase of myo-
cardial fibrosis development [4]. In support of the role
for TGFβ, inhibition of TGFβ using antibodies [9] ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sulted in reduced myocardial fibrosis. However, TGFβ is
a pleiotropic cytokine that has both pro-inflammatory
and anti-inflammatory functions, making treatment
strategies based on its reduction difficult, as serious
deleterious effects have been reported, such as increased
mortality after myocardial infarction [11]. Other
antibody-based therapeutic strategies attempted in ani-
mal models have included targeting IL23R, platelet-
derived growth factor-receptor, and the TGFβ down-
stream mediator connective tissue growth factor
(CTGF), without any antibody-based therapy in clinical
use to date [12,13].
In the present study, we show that non-specific anti-
body, similar to those used as controls for therapies used
to treat myocardial fibrosis can in fact worsen the onset
of fibrosis in the AngII-induced model. We provide evi-
dence that the mechanism for this apparent paradoxical
observation is mediated by increased pro-inflammatory
cytokine production and is not dependent on the specifi-
city of the antibody. In fact, the worsened fibrotic re-
sponse to whole antibody disappeared with treatment
using Fab fragments, suggesting that an Fc-mediated ac-
tivation of infiltrated cells was key to the exacerbated fi-
brotic response.Figure 1 Antibody administration and fibrosis. Animals exposed to Ang
vein injection. Myocardial cross-sections were stained with Sirius red to ass
deposited within whole cross-sections was assessed using image analysis s
Col1A1 (B). Transcript levels are reported relative to the housekeeping gene
shown at 10x. *P <0.05, **P <0.01 compared to saline, +P <0.05, ++P <0.01Results
Effect of antibody on early myocardial fibrosis
The addition of non-specific antibody by tail-vein injec-
tion to the AngII model of myocardial fibrosis over
3 days resulted in a significant increase of the fibrotic
area within the myocardium. The amount of fibrosis
was significantly increased after mIgG treatment, with
26.34 ± 3.03% of myocardium affected compared to
11.29 ± 1.20% with AngII alone, and with a more dis-
persed pattern of collagen deposition (Figure 1A, C, D).
The mRNA expression of Col1A1, a subunit of type I
collagen, the most prolific structural collagen in the
myocardium, also increased in the myocardium of ani-
mals exposed to AngII, but did not increase further in
the AngII + mIgG group (Figure 1B).
Similarly, the amount of cellular infiltration assessed
using a standardized grid-affected method after staining
whole myocardial cross-sections with hematoxylin and
eosin (H&E) was significantly higher in animals receiving
the non-specific mIgG (24.42 ± 3.67%) when compared
to AngII alone (14.27 ± 1.22; P <0.01) (Figure 2A, B, C).
The phenotype of the cellular infiltrate in both groups
included cells expressing both α-smooth muscle actin
(SMA) and CD45 in keeping with a phenotype for fibro-
cytes that co-express monocyte and mesenchymalII for 3 days were concurrently administered non-specific mIgG by tail
ess the AngII development of fibrosis. The percentage of collagen
oftware (A) and qPCR was used to assess myocardial expression of
18S. Representative images of AngII (C), and AngII + mIgG (D) are
compared to AngII.
Figure 2 Antibody administration and cellular infiltration. Animals exposed to AngII for 3 days were concurrently administered mIgG by tail
vein injection. The amount of cellular infiltrate within whole cross-sections was assessed using a grid-scoring method of whole myocardial
cross-sections after H&E stain and the results reported as percentage of area affected (A). Representative H&E stained sections of AngII (B) and
AngII + mIgG (C) are shown at 5x and areas of infiltration are highlighted by black borders. Immunofluorescent staining of CD45 (green) and SMA
(red) indicate dual staining (yellow) within areas of infiltration in AngII (D), AngII + mIgG (E) treated myocardium, with representative images
shown at 63x and an additional 4x digital magnification of an area of dual staining shown (F). *P <0.05, **P <0.01 compared to saline, +P <0.05,
++P <0.01 compared to AngII.
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cursors to myofibroblasts and as such important ECM
producing effector cell seen in fibrotic disorders ([15])
(Figure 2D, E, F). Taken together, our findings demon-
strate that antibody addition to AngII-exposed animals
in fact results in worsening the fibrotic changes within
the myocardium.
Increased fibrosis is not due to increased complement
activation
A potential mechanism by which the addition of mIgG
exacerbated fibrosis is complement-mediated cytotox-
icity. In order to assess if complement is involved we
stained cross-sections of myocardium using anti-C4d
antibody. In the AngII alone and AngII + mIgG groups
we observed positive C4d staining, primarily located in
areas of cellular accumulation within the myocardium
(Figure 3A, B, C). Given the similar amount of C4d in
both AngII and AngII + mIgG groups, this suggests that
complement activation was not specific to the addition
of mIgG. Further support for the lack of deposition of
IgG in the myocardium is provided by a lack of identifi-
able immunohistochemical staining for IgG within themyocardium of any of the groups (Additional file 1).
Taken together, our findings indicate that the increased
fibrotic response with the addition of mIgG is not due to
complement activation.
Increased fibrosis is secondary to increased
pro-inflammatory cytokines within the myocardium
The overall increase in mononuclear cells, many of
which expressed markers of fibrocytes (CD45+/SMA+)
within the myocardium in the AngII + mIgG group sug-
gests that inflammatory signaling may be contributing to
the enhanced cellular response to AngII. We therefore
assessed the mRNA expression of two known potent in-
flammatory mediators, tumour necrosis factor-α (TNFα)
and interleukin 1β (IL1β) within the myocardium
[16,17]. TNFα and IL1β mRNA expression were not sig-
nificantly affected by exposure to AngII alone compared
to saline, but increased significantly with the addition of
mIgG (TNFα 7.72 ± 0.87 fold; IL1β 8.08 ± 1.72 fold;
P <0.01) (Figure 4A, B). We then looked at TGFβ
as a predominant pro-fibrotic cytokine normally up-
regulated in animals exposed to AngII [18,19]. As previ-
ously shown, there was a significant increase in TGFβ
Figure 3 Complement activation. Immunohistochemical staining against C4d was used to assess the amount of complement activation in
myocardium of animals exposed to saline (A), AngII (B), and AngII + mIgG (C) for 3 days. Representative images are shown at 20X.
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relative to saline control (Figure 4C). However, in animals
that received AngII +mIgG there was a significant reduc-
tion in TGFβ expression when compared to AngII alone
that remained higher than in saline control (3.05 ± 0.35 vs.
4.48 ± 0.38 fold) (Figure 4C). Our findings suggest that the
addition of mIgG may be favoring pro-inflammatory sig-
naling (TNFα and IL1β) as opposed to anti-inflammatory
signaling (TGFβ), contributing to the activation of the
cells within the myocardium and ultimately resulting in
increased fibrosis.
Fibrocytes enriched from PBMCs are activated by mIgG
We have previously demonstrated that a large portion of
infiltrating cells after AngII exposure are monocyte-
derived fibrocytes and that isolated circulating peripheral
blood mononuclear cells (PBMCs) can be made to dif-
ferentiate into fibrocytes under specific conditions
[4,20]. This explains in part why we used human PBMCs
in addition to their easy availability to evaluate the im-
pact of exposure to IgG. One should note that human
and murine FcγR subclasses are not homologous, but
are able to bind IgG that originate from the oppositeFigure 4 Pro-inflammatory regulation. qPCR was used to assess myocar
AngII + mIgG exposure for 3 days. Transcript levels are reported relative to
+P <0.05, ++P <0.01 compared to AngII.species as previously shown by others, which supports
our experimental approach [21,22]. We therefore incu-
bated PBMCs in vitro with mIgG for 48 h. This exposure
resulted in increased production of the pro-inflammatory
cytokines IL1β, TNFα, and IL6 measured by ELISA with
IL6 reaching significance compared to saline control
(Figure 5). This suggests that mononuclear infiltrating
cells originating from the circulation can be directly af-
fected by the presence of mIgG, suggesting a potential
mechanism for our observed increase in fibrosis in vivo.
In support of our findings is previously published evi-
dence that IgG can activate mononuclear cells, resulting
in the differentiation of monocytes and the production of
pro-inflammatory cytokines [23,24].
Increased fibrosis seen in animals receiving mIgG is
prevented by using Fab fragments or mIgM
Fc receptor recognition and binding of the Fc fragment
of IgG molecules leads to increased inflammatory signal-
ing [25]. We therefore removed the Fc portion from the
mIgG molecules, and treated AngII exposed animals
with the resulting Fab fragment (Figure 6). When AngII
exposed animals were treated with Fab, myocardialdial expression of TNFα (A), IL1β (B), and TGFβ (C) after saline, AngII, or
the housekeeping gene 18S. *P <0.05, **P <0.01 compared to saline,
Figure 5 PBMC stimulation with mIgG. Isolated PBMCs were
exposed to mIgG at 25 mg/mL. Supernatants were collected and
ELISAs were used to assess for TNFα, IL1β, and IL6 production,
reported relative to saline control (solid line). *P <0.05 compared
to saline.
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posed animals treated with whole mIgG (14.49 ± 2.23 vs.
26.34 ± 3.03%; P <0.05). In order to further support our
observation we tested the impact of adding whole mIgM
to AngII exposure. IgM is not recognized by FcγRs, and
so does not activate mononuclear cells in the circulation
in an Fc-mediated manner [25]. Similar to animals that
received AngII + Fab, mice exposed to AngII + mIgM did
not have elevated fibrosis compared to animals exposed
only to AngII. Importantly, fibrosis was significantly re-
duced compared to the AngII + mIgG group (12.74 ±
2.59%). Taken together, these findings suggest that the
mechanism behind the exacerbation of fibrosis was Fc-
mediated.Figure 6 AngII plus Fab or IgM. Animals were exposed to AngII
for 3 days and concurrently Fab fragments or IgM were injected by
tail vein for a total of 3 days. Fibrosis was semi-quantified by image
analysis software of Sirius red stained whole cross-sections of
myocardium. *P <0.05 compared to saline.Discussion
There are no existing therapies available to treat estab-
lished myocardial fibrosis. In the present study, animals
exposed to AngII were administered a non-specific
mouse IgG, such as would be used as a control in tar-
geted antibody therapies for fibrotic diseases. Surpris-
ingly, the introduction of antibody to this model of
myocardial fibrosis increased the amount of fibrosis in
the first few days of exposure. Our observations were ro-
bust as we provided direct correlation of increased fibro-
sis with increased cellular infiltration, as previously
described [6]. We also used two different preparations of
mIgG antibodies with similar results further supporting
the observations (reported results were pooled). We
therefore sought to investigate the potential mechanisms
by which mIgG given to animals could affect myocardial
fibrosis. This is particularly relevant as investigators are
currently working on a multitude of targets using anti-
body approaches.
Evidence for the direct binding of the IgG molecules
within the myocardium was assessed, as this could have
contributed to antibody-dependent complement medi-
ated cytotoxicity [26]. Complement activation occurs
when complement component 1 recognizes surface
bound IgG, leading to initiation of a cascade that ultim-
ately results in cell lysis and deposition of the split prod-
uct C4d [27]. C4d deposition is a well-described
histological technique to identify areas of classical com-
plement activation [26]. We found evidence of comple-
ment activation based on C4d deposition in all animals
exposed to AngII with no evidence of significant differ-
ences between groups in which antibody was added. This
suggests that while complement may be involved in
AngII-induced myocardial fibrosis, it was not responsible
for the increase in fibrosis observed after the addition of
antibody. We did not explore the lectin pathway of acti-
vation in which complement activation occurs without
immunoglobulin.
The AngII exposure model of myocardial fibrosis is
one in which myocardial inflammation potentially plays
a large role based on early myocardial inflammatory cell
migration and pro-inflammatory effects of AngII [6,28].
Particularly relevant are monocyte-derived fibrocytes
that have been identified as an important cell type in the
development of AngII-mediated myocardial fibrosis
[6,8]. We observed that in animals exposed to AngII and
antibody there was a significant increase in the pro-
inflammatory cytokines TNFα and IL1β. This is particu-
larly relevant as these cytokines are produced primarily
by monocytes and macrophages, which can be activated
by the binding of IgG to Fc gamma receptors I and IIA
(FcγRs) [25,29,30]. Mouse (and human) FcγRs have higher
affinity for certain IgG subclasses, which have been exten-
sively reviewed by others [21]. The administration of
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implies that we do not know which FcγR is recognizing
the exogenous IgG, or if it is an activating or inhibitory re-
ceptor subtype that is involved. However, as both macro-
phages and fibrocytes are monocyte-derived cells, it
follows that mIgG may also be mediating the activation of
fibrocytes that infiltrate the myocardium in our model. To
test this hypothesis, we exposed PBMCs containing mono-
cytes to mIgG. Using this in vitro assay we were able to
show that the addition of mIgG can activate PBMCs influ-
encing the production of pro-inflammatory cytokines
IL1β, TNFα, and IL6.
Another potential mechanism of action of mIgG that
could enhance the AngII-induced inflammatory re-
sponse is through the ability of IgG to form aggregates
[31]. The FcγRs preferentially bind monomeric (FcγI) or
aggregate IgG (FcγRII, III) [32]. In general, protein ag-
gregates interact with B cell receptors, activating B cells
or targeting protein to major histocompatibility complex
type II [33]. Additionally, IgG aggregates can cause clus-
tering of FcγRs, contributing to inflammation [31]. The
presence of only a small fraction of aggregated protein is
capable of eliciting a response [33]. In the current study
risk factors for aggregation were avoided; preparations
were not heated or stored in conditions reported to con-
tribute to protein aggregate formation and preparations
were filtered prior to injection [33]. In addition, the
mIgG was stored at 2 mg/mL, and the dosage utilized
for IV administration was 0.25 mg/mL, both of which
are well below the concentration at which IgG spontan-
eously forms aggregates (30 mg/mL) [31]. Further sup-
port for the response elicited after mIgG administration
in the current study is provided by the reported inhib-
ition of fibrocyte differentiation by aggregated IgG [32].
The treatment of AngII-exposed mice with only the
Fab fragment of the mIgG, which were produced by re-
moving the Fc portion and therefore the antibodies abil-
ity to signal through FcγRs did not result in an increase
in fibrosis development compared to AngII alone. Simi-
lar results were observed when animals were exposed to
IgM in addition to AngII, supporting our hypothesis that
the observed increase of fibrosis with IgG was based on
the Fc portion interactions. Taken together, we have
shown that the use of mIgG in animals receiving AngII
can enhance the primary inflammatory reaction within
the myocardium and this appears to be mediated by Fc-
mediated activation of monocyte-derived cells.
One should note that the present study was not de-
signed to characterize the exact phenotype of infiltrated
cells or whether fibrocytes or macrophages were respon-
sible for Fc activation. However, Pilling et al. previously re-
ported that the blockage of FcγR reduced the ability of
circulating PBMCs to differentiate into fibrocytes, linking
Fc activation to infiltrated cells in models of myocardialfibrosis [20]. It is also possible that stimulation of FcγRs
may have a role in increasing macrophage differentiation
from a pro-inflammatory to anti-inflammatory/pro-fi-
brotic state, ultimately resulting in an increase in fibrosis
[29]. However, this has yet to be confirmed in the AngII
model of myocardial fibrosis. Furthermore, our findings
suggest that mIgG in combination with AngII was associ-
ated with less TGFβ, suggesting a reduction in the anti-
inflammatory/pro-fibrotic phenotype. This would result in
an important change in the cytokine environment and bal-
ance between inflammation/cellular infiltration and reso-
lution, potentially resulting in increased fibrosis.
While there is no established anti-fibrotic therapy in
clinical use, there are a number of previous studies that
have illustrated the potential applicability of neutralizing
antibodies to reduce fibrosis in animal models. Such
studies often report only changes between specific, tar-
geted antibody and the non-specific control antibody
treatments [34,35]. However, others have reported data
suggesting that there are differences between AngII
alone and AngII + IgG control antibody treatments, al-
though these differences, such as in number and type of
infiltrating cells were not investigated in depth [12].Conclusions
The present study raises important considerations in the
design of future antibody-based therapies for conditions
in which inflammation can have a profound role. Our
findings suggest that the Fc portion of the antibody may
significantly upregulate inflammation, influencing any
therapy used. This could also explain in part, why prior
attempts in clinical trials using systemic administration
of antibody for fibrotic disorders have largely failed
[36-38]. These trials have targeted TGFβ, TGFβRII,
TIMP1, and TNFα, which had promising anti-fibrotic re-
sults with in vitro and in vivo animal models [13,39,40].
In summary, we were able to demonstrate that non-
specific antibody administered to animals exposed to
AngII can result in worsening of myocardial fibrosis by
increasing pro-inflammatory cytokine production in the
myocardium via Fc portion mediated activation.Methods
Animals
All work was performed in accordance with the Canadian
Council on Animal Care and approved by the local
Dalhousie’s University Committee on Laboratory Animals.
Male C57Bl/6 mice between 7 and 8 weeks of age were
purchased from the Jackson Laboratory (Bar Harbour,
ME, USA) and were housed within the Carleton Animal
Care Facility at Dalhousie University. Mice were provided
food and water ad libitum for 1 week prior to
experimentation.
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Two preparations of mIgG were used and the results
were pooled as there was no significant difference be-
tween the preparations for any of the parameters tested.
Non-specific mIgG antibody was purchased from Sigma
or isolated from mouse serum. Whole mIgG was frag-
mented and Fc portion removed using the Pierce Fab
Preparation kit (Fisher), following the manufacturer’s in-
structions. In brief, mIgG in PBS was prepared in dilu-
tion buffer and desalted. The mIgG was then mixed with
agarose-immobilized papain in a spin column and incu-
bated for 3 h followed by centrifugation to elute digested
antibody. The Fab portion was purified from the digest
using a Protein A column, after which Fc fragments and
remaining whole IgG were eluted. Protein concentra-
tions were measured by absorbance at 280 nm using a
Nanodrop 2000 spectrophotometer (Thermo Fisher),
and all elution fractions were run on a non-reducing gel
to assess purity (Additional file 2).
AngII infusion and immunoglobulin intravenous injection
Animals were randomly assigned to the following groups;
1- AngII (2.0 μg/kg/min; Sigma Aldrich, Oakville, ON,
Canada; n = 7), 2- AngII +mIgG (1 mg/kg/d; n = 6), 3-
AngII + Fab (1 mg/kg/d; n = 4), 4- AngII +mIgM (1 mg/
kg/d; Biolegend, San Diego, CA, USA; n = 4) and add-
itional saline controls (saline+/-mIgG or Fab; n = 10). Ani-
mals had mini osmotic pumps containing AngII or saline
implanted under general anesthesia as previously reported
[6]. In short, animals were anesthetized with isoflurane
(Baxter Healthcare Corp., New Providence, NJ, USA) in
oxygen at which point a 1 to 2 cm mid-scapular skin inci-
sion was made and a mini osmotic pump (Alzet, Palo Alto,
CA, USA) containing AngII or saline was inserted sub-
cutaneously. The pumps remained in for 3 days during
which the animals were provided food and water ad libi-
tum and observed for signs of morbidity. Mouse IgG, Fab,
and IgM were diluted in sterile saline and equalized to 100
μL, which was injected via the tail vein daily starting on
the day of pump insertion surgery, for a total of three
doses.
Tissue harvest
Hearts from experimental animals were harvested and
weighed, then divided into three sections. The base sec-
tion of the heart was processed for histological examin-
ation with the apical section split vertically and these
pieces were snap frozen in liquid nitrogen immediately
for molecular analysis.
Histological analysis
Hearts were processed for histological assay by fixing
with 10% formalin for 24 h or protecting with sucrose/
OCT followed by snap freezing. Formalin fixed tissuewas paraffin-embedded and serially sectioned on a
microtome (5 μm). Basic myocardial histology and cellu-
lar infiltration were examined using heart cross-sections
stained with hematoxylin and eosin. A blinded observer
quantified the infiltrating cells by counting the number
of grids affected within an image of an entire heart
cross-section at 50x magnification (1 section per ani-
mal), based on a previously published grid-scoring
method to quantify the degree of cellular infiltration be-
tween groups [6]. Collagen was detected using Sirius red
and fast green stains and was semi-quantified as previ-
ously described [4]. Briefly, the entire heart cross-section
at 5x was analyzed using image analysis software to cal-
culate the percentage of red pixels over the area of the
cross-section.
Immunohistochemistry for C4d (Hycult Biotech,
Plymouth Meeting, PA, USA) was performed on paraffin
embedded tissues, which were deparaffinized and treated
for antigen retrieval prior to staining. Briefly, endogen-
ous peroxidases were quenched with 3% hydrogen per-
oxide; endogenous biotin was blocked (DAKO Biotin
Blocking System, DakoCytomation); and non-specific
staining was blocked with normal goat serum. Sections
were incubated with primary antibody, followed by a
specific biotin-conjugated secondary antibody. The anti-
body complexes were then conjugated to an Avidin-
biotin complex (Vectastain ABC kit; Vector, Burlington,
CA, USA) and developed using 3,3′ diaminobenzidine
as the chromogen (DAB; DakoCytomation). Light mi-
croscopy was performed and pictures were captured
using a Zeiss AxioplanII with an Axiocam HRC colour
camera. Images were analyzed in Adobe Photoshop 5.0.
Immunofluorescence staining
Sucrose protected, frozen sections were fixed in 4% par-
aformaldahyde, permeabilized with 0.03% Triton X-100,
blocked against non-specific antibody binding with 10%
normal goat serum, and stained for CD45 (BD Biosci-
ences, Mississauga, ON, Canada) and alpha-smooth
muscle actin (SMA; Sigma). Antibodies were detected
using anti-host specific Alexa fluorescently labeled sec-
ondary antibodies (Invitrogen). Images were captured
with a Zeiss Axiovert 200 inverted microscope with a
Hamamatsu ORCA-R2 digital camera with an AttoArc 2
HBO 100 W lamp.
Relative quantitative polymerase chain reaction (qPCR)
Total RNA was isolated from snap frozen heart sections
using TRIzol (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s protocol. First strand cDNA was syn-
thesized from RNA using iScript cDNA Synthesis Kit
(Biorad, Hercules, CA, USA). The qPCR was completed
using iQ SYBR Green Supermix (Biorad) and the iQ Multi-
colour Real-Time PCR Detection System thermocycler
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no-template control samples were run with each thermo-
cycling. Melt curves were run after cycling to ensure tar-
get specificity. Primers were designed against mRNA













TTCT-3′. Expression was normalization to the 18S ribo-
somal gene using the Pfaffl method.Cell isolation and culture
PBMCs were isolated from healthy volunteers. The aver-
age donor age was 27.3 ± 2.5 years and the group in-
cluded four men and eight women, none of who had any
history of hypertension, cardiovascular disease, or treat-
ment for hypertension. Briefly, whole blood was col-
lected in EDTA containing Vacutainer tubes, diluted in
Dulbecco’s phosphate buffered saline (dPBS; Invitrogen)
containing 2% fetal bovine serum (FBS; Invitrogen) and
processed over Ficoll-Paque Plus gradient (GE Health-
care, Waukesha, WI, USA). The PBMC containing layer
was isolated, washed, and cells plated in RPMI media
with 10% FBS, 2 mM L-glutamine, 100 mg/mL strepto-
mycin, and 100 U/mL Penicillin.
Isolated PBMCs were treated with mIgG (25 μg/mL)
for 48 h. Supernatant was collected, centrifuged to re-
move cell debris and then stored at -80°C. Relative pro-
duction of TNFα, Ilβ, and IL6 were assessed using
commercial ELISA kits, following the manufacturer’s in-
structions (IL1β and TNFα, Abcam; IL6, BD Biosciences,
Mississauga, ON, Canada).Statistical analysis
Data are represented as mean ± SEM. One-way ANOVA
tests were completed using the Bonferroni post-test to
compare the experimental groups to the relative con-
trols. All qPCR results were evaluated based on the one-
tailed T-test to compare changes in relative mean ex-
pression. All statistical calculations were computed using
GraphPad Prism4 software and significance was deter-
mined if P ≤0.05.Additional files
Additional file 1: Anti-IgG immunohistochemistry.
Immunohistochemical staining against mIgG was used to assess the
amount of bound IgG in myocardium of animals exposed to saline (A),
AngII (B), and AngII + mIgG (C) for 3 days. Representative images are
shown at 20x.
Additional file 2: Non-reducing gel of digested Fab. Non-reducing
PAGE (10%) was run to assess the quality of digestion of whole mIgG
and isolation of the Fab fragment.
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